Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Other Accumulated Expenses (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Other Accumulated Expenses for 11 consecutive years, with $48.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Accumulated Expenses rose 19.11% year-over-year to $48.5 million, compared with a TTM value of $48.5 million through Sep 2025, up 19.11%, and an annual FY2024 reading of $41.8 million, changed 0.24% over the prior year.
  • Other Accumulated Expenses was $48.5 million for Q3 2025 at Heron Therapeutics, up from $46.2 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $52.4 million in Q2 2023 and bottomed at $24.7 million in Q1 2021.
  • Average Other Accumulated Expenses over 5 years is $38.6 million, with a median of $40.3 million recorded in 2023.
  • The sharpest move saw Other Accumulated Expenses dropped 23.68% in 2021, then soared 58.2% in 2023.
  • Year by year, Other Accumulated Expenses stood at $25.9 million in 2021, then skyrocketed by 49.09% to $38.6 million in 2022, then increased by 8.57% to $41.9 million in 2023, then fell by 0.24% to $41.8 million in 2024, then rose by 16.15% to $48.5 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for HRTX at $48.5 million in Q3 2025, $46.2 million in Q2 2025, and $47.4 million in Q1 2025.